UPDATE - PIMCO Closed-End Funds Declare Monthly Common

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
UPDATE - PIMCO Closed-End Funds Declare Monthly Common Share Distributions

NEW YORK, NY--(Marketwired - Sep 2, 2015) - The Boards of Trustees/Directors of the PIMCO closed-end funds (each, a "Fund" and, collectively, the "Funds") have declared a monthly distribution for each Fund's common shares as summarized below. The distributions are payable on October 1, 2015 to shareholders of record on September 11, 2015, with an ex-dividend date of September 9, 2015.

             
Fund   NYSE Symbol   Monthly Distribution Per Share   Change from Prior Monthly Distribution Per Share
PIMCO Corporate & Income Strategy Fund   (NYSE: PCN)   $ 0.112500    
PIMCO Corporate & Income Opportunity Fund   (NYSE: PTY)   $ 0.130000    
PIMCO Global StocksPLUS® & Income Fund   (NYSE: PGP)   $ 0.183350    
PIMCO High Income Fund   (NYSE: PHK)   $ 0.103460   (0.018415)
PIMCO Income Opportunity Fund   (NYSE: PKO)   $ 0.190000    
PIMCO Strategic Income Fund, Inc.   (NYSE: RCS)   $ 0.080000    
PCM Fund, Inc.   (NYSE: PCM)   $ 0.080000    
PIMCO Income Strategy Fund   (NYSE: PFL)   $ 0.090000    
PIMCO Income Strategy Fund II   (NYSE: PFN)   $ 0.080000    
PIMCO Dynamic Income Fund   (NYSE: PDI)   $ 0.220500   0.010500
PIMCO Dynamic Credit Income Fund   (NYSE: PCI)   $ 0.164063   0.007813
PIMCO Municipal Income Fund   (NYSE: PMF)   $ 0.081250    
PIMCO California Municipal Income Fund   (NYSE: PCQ)   $ 0.077000    
PIMCO New York Municipal Income Fund   (NYSE: PNF)   $ 0.057000    
PIMCO Municipal Income Fund II   (NYSE: PML)   $ 0.065000    
PIMCO California Municipal Income Fund II   (NYSE: PCK)   $ 0.053750    
PIMCO New York Municipal Income Fund II   (NYSE: PNI)   $ 0.066250    
PIMCO Municipal Income Fund III   (NYSE: PMX)   $ 0.062300    
PIMCO California Municipal Income Fund III   (NYSE: PZC)   $ 0.060000    
PIMCO New York Municipal Income Fund III   (NYSE: PYN)   $ 0.052500    
             

Certain of the Funds announced distribution changes this month. PDI's and PCI's monthly distributions were increased by $0.010500 per share and $0.007813 per share, respectively. PHK's distribution was reduced by $0.018415 per share.

Generally, the changes in distributions for PHK, PCI and PDI take into account many factors, including but not limited to, each such Fund's current and expected earnings, the overall market environment and PIMCO's current economic and market outlook.

Distributions from PMF, PML, PMX, PCQ, PCK, PZC, PNF, PNI and PYN are generally exempt from regular Federal income taxes. In addition, distributions from PCQ, PCK and PZC are also generally exempt from California state income taxes, and distributions from PNF, PNI and PYN are generally exempt from New York State and city income taxes. There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.

Distributions may include ordinary income, net capital gains and/or returns of capital. Generally, a return of capital occurs when the amount distributed by a Fund includes a portion of (or is comprised entirely of) your investment in the Fund in addition to (or rather than) your pro-rata portion of the Fund's net income or capital gains. A Fund's distributions in any period may be more or less than the net return earned by the Fund on its investments, and therefore should not be used as a measure of performance or confused with "yield" or "income." A return of capital is not taxable; rather it reduces a shareholder's tax basis in his or her shares of the Fund. If a Fund estimates that a portion of its distribution may be comprised of amounts from sources other than net investment income, such Fund will notify shareholders of the estimated composition of such distribution through a separate written notice. Such notices are provided for informational purposes only, and should not be used for tax reporting purposes. Final tax characteristics of all Fund distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

A Fund's distribution rate may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors. There can be no assurance that a change in market conditions or other factors will not result in a change in a Fund distribution rate at a future time. 

Certain Funds may engage in investment strategies, including the use of derivatives, to, among other things, generate current, distributable income without regard to possible declines in the Fund's net asset value. A Fund's income and gain-generating strategies, including certain derivatives strategies, may generate current income and gains for monthly distributions even in situations when the Fund has experienced a decline in net assets, including losses due to adverse changes in securities markets or the Fund's portfolio of investments, including derivatives. Consequently, common shareholders may receive distributions and owe tax at a time when their investment in the Fund has declined in value, which tax may be at ordinary income rates. Also, the tax treatment of certain derivatives may be open to different interpretations. Any recharacterization of payments made or received by a Fund pursuant to derivatives potentially could affect the amount, timing or character of Fund distributions. In addition, the tax treatment of such investment strategies may be changed by regulation or otherwise.

The Funds' daily New York Stock Exchange closing market prices, net asset values per share, as well as other information, including updated portfolio statistics and performance are available at pimco.com/closedendfunds or by calling the Funds' shareholder servicing agent at (844) 33-PIMCO. Updated portfolio holdings information about a Fund will be available approximately 15 calendar days after such Fund's most recent fiscal quarter end, and will remain accessible until such Fund files a Form N-Q or a shareholder report for the period which includes the date of the information.

About PIMCO

PIMCO is a leading global investment management firm with offices in 12 countries throughout North America, Europe and Asia. Founded in 1971, PIMCO offers a wide range of innovative solutions to help millions of investors worldwide meet their needs. Our goal is to provide attractive returns while maintaining a strong culture of risk management and long-term discipline. PIMCO is the investment manager of the Funds' and is owned by Allianz S.E., a leading global diversified financial services provider.

Except for the historical information and discussions contained herein, statements contained in this news release constitute forward-looking statements. These statements may involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including the performance of financial markets, the investment performance of PIMCO's sponsored investment products and separately managed accounts, general economic conditions, future acquisitions, competitive conditions and government regulations, including changes in tax laws. Readers should carefully consider such factors. Further, such forward-looking statements speak only on the date at which such statements are made. PIMCO undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statement.

This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. PIMCO and YOUR GLOBAL INVESTMENT AUTHORITY are trademarks or registered trademarks of Allianz Asset Management of America L.P. and Pacific Investment Management Company LLC, respectively, in the United States and throughout the world. ©2015, PIMCO

For information on PIMCO Closed-end Funds: Financial Advisors: (800) 628-1237 Shareholders: (844) 337-4626 or (844) 33-PIMCO PIMCO Media Relations: (212) 739-4212

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 454

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 77

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading